1/2 Collaborative Union for Cancer Research, Education and Disparities (CURED)

已治愈的整体摘要 丹·L与德克萨斯州贝勒医学院邓肯综合癌症中心 南方大学(TSU)联合提交了一份P20申请，以建立癌症合作伙伴关系 研究、教育和推广。DLDCCC是美国国家癌症研究所(NCI)指定的癌症中心。Tsu 是全国最大的历史上最大的黑人学院和大学(HBCU)，服务于服务不足 人口和代表不足学生(ISUPS)。BCM和TSU已经成功地 合作。这种关系最近通过TSU的U54生物医学和医疗中心得到了加强 少数族裔健康研究“，在那里，BCM的教职员工在合作的癌症差异方面密切合作 社区教育和外展。这个P20项目为TSU和BCM提供了一个绝佳的机会 扩大协作。我们提出了BCM-TSU P20计划“癌症研究合作联盟， 教育和差距“(治愈)，这将促进利用我们的互补优势进行强有力的合作。 总体目标是创建一个共享基础设施，为癌症提供最佳环境 研究、教育、社区推广和职业发展，并使生物医学劳动力多样化。 治愈是在每个机构的高级领导的指导下建立的，反映在重要的 为这一伙伴关系提供机构支持。BCM承诺在四年内每年提供16万美元的成本匹配基金， 拨款50,000元予试验计划2，为期一年，并承诺拨款支援台大暑期学生的培训 在癌症研究教育项目中。Tsu已承诺退还间接成本分配额 到每年98,000美元。TSU的所有调查人员都是DLDCCC的成员。因此，每个机构的领导人都是 致力于增强P20伙伴关系，以解决URM和未得到充分服务的人之间的癌症健康差异 休斯顿的人口。我们的目标是(1)在BCM和TSU之间建立癌症合作联盟 研究、教育和社区外展。我们将(A)在这两个机构建立健全的办公室， 为相关活动提供协调，评估当前项目的进展情况，并确保 创新的试点项目；(B)集中机构资源满足教员/实习生的研究需求(C)领导癌症 为TSU学生提供的研究和职业发展计划，包括有指导的癌症研究，以及 教育课程、新兴技术实践培训和专业发展；(D)建立 BCM/TSU综合外展计划，以解决长凳上、床边和内部的癌症差异 (2)支持一系列协作创新的癌症研究试点项目。 总体影响：我们确信，拟议的治愈方案将增强癌症研究教育能力 Tsu，促进多样化的研究队伍，并提高BCM/DLDCCC在开发和 持续的研究项目侧重于癌症健康差异。我们将发展可持续研究 向NIH/其他联邦/非联邦机构提供独立和协作应用程序的能力。

CURED Overall Abstract Dan L Duncan Comprehensive Cancer Center (DLDCCC) at Baylor College of Medicine (BCM) and Texas Southern University (TSU) are jointly submitting a P20 application to build a collaborative partnership in cancer research, education, and outreach. DLDCCC is a National Cancer Institute (NCI) designated cancer center. TSU is one of the nation’s largest Historically Black Colleges and Universities (HBCU) serving underserved populations and underrepresented students (ISUPSs). BCM and TSU have had several successful collaborations. This relationship was strengthened recently through TSU’s U54 “Center for Biomedical and Minority Health Research”, where BCM faculty have partnered closely on collaborative cancer disparities community education and outreach. This P20 program provides an excellent opportunity for TSU and BCM to expand collaborations. We propose a BCM-TSU P20 program “Collaborative Union for Cancer Research, Education and Disparities” (CURED) that will foster strong collaborations utilizing our complementary strengths. Overall objectives are to create a shared infrastructure that will provide an optimal environment for cancer research, education, community outreach, and career development and diversify the biomedical workforce. CURED was established under the direction of senior leadership at each institution, reflected in the significant institutional support for this partnership. BCM has committed $160,000/year for four years in cost matching funds, $ 50,000 for Pilot project 2 for one year, and committed funds to support the training of TSU summer students in the Cancer Research Education Program. TSU has committed to return the Indirect Cost allocation amounting to $98,000 each year. All TSU investigators are members of the DLDCCC. Leaders of each institution are thus committed to empower the P20 partnership to address cancer health disparities among URM and underserved populations in Houston. Our goals are to (1) establish a collaborative alliance between BCM and TSU for cancer research, education, and community outreach. We will (a) establish CURED offices in both institutions that will provide coordination for relevant activities, evaluate progress of current projects, and ensure a pipeline of innovative pilot projects; (b) centralize institutional resources for faculty/trainee research needs (c) lead a cancer research and career development program for TSU students that includes mentored cancer research, an educational curriculum, hands-on training in emerging technologies, and professional development; (d) build a BCM/TSU comprehensive outreach program to address cancer disparities at the bench, bedside, and within the community; and (2) to support a pipeline of collaborative innovative cancer research pilot projects. Overall Impact: We are certain that the proposed CURED will enhance cancer research education capacity at TSU, promote a diverse research workforce, and improve BCM/DLDCCC’s effectiveness in developing and sustaining research programs focused on cancer health disparities. We will develop sustainable research capacity leading to independent and collaborative applications to the NIH/other Federal/Non-federal agencies.